EKF 2024: Interview with Stefan Weber of Newron Pharmaceuticals скачать в хорошем качестве

EKF 2024: Interview with Stefan Weber of Newron Pharmaceuticals

At the Deutsches Eigenkapitalforum in Frankfurt, we talked to Newron Pharmaceuticals’ CEO Stefan Weber about the company’s groundbreaking advancements in schizophrenia treatment and their plans for 2024/2025. Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com